{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:28:02Z","timestamp":1788449282595,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,22]]},"DOI":"10.7759\/cureus.65141","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:24:05Z","timestamp":1721694245000},"source":"Crossref","is-referenced-by-count":9,"title":["Comparison of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Demeke E","family":"Agago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najma","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariga Sai","family":"Ajay Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Arsalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet","family":"Kaur Dhanjal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin R","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1817385\u00a0","article-title":"The pharmacotherapeutic management of gastroesophageal reflux disease (GERD)","volume":"22","author":"Chapelle N","year":"2021","unstructured":"Chapelle N, Ben Ghezala I, Barkun A, Bardou M. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opin Pharmacother. 2021, 22:219-27. 10.1080\/14656566.2020.1817385\u00a0","journal-title":"Expert Opin Pharmacother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313589","article-title":"Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis","volume":"67","author":"Eusebi LH","year":"2018","unstructured":"Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018, 67:430-40. 10.1136\/gutjnl-2016-313589","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz PO","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013, 108:308-28; quiz 329. 10.1038\/ajg.2012.444","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225631.07039.6d","article-title":"Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics","volume":"41","author":"Fass R","year":"2007","unstructured":"Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007, 41:131-7. 10.1097\/01.mcg.0000225631.07039.6d","journal-title":"J Clin Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz PO","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022, 117:27-56. 10.14309\/ajg.0000000000001538","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03235.x","article-title":"Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis","volume":"25","author":"Katz PO","year":"2007","unstructured":"Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2007, 25:617-28. 10.1111\/j.1365-2036.2006.03235.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5056\/jnm15105","article-title":"Unmet needs in the treatment of gastroesophageal reflux disease","volume":"21","author":"Dickman R","year":"2015","unstructured":"Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015, 21:309-19. 10.5056\/jnm15105","journal-title":"J Neurogastroenterol Motil"},{"key":"ref8","article-title":"Pharmacogenetics of the proton pump inhibitors: a systematic review","volume":"23","author":"Chong E","year":"2023","unstructured":"Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023, 23:460-71.","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16295","article-title":"Review article: potassium-competitive acid blockers for the treatment of acid-related disorders","volume":"53","author":"Abdel-Aziz Y","year":"2021","unstructured":"Abdel-Aziz Y, Metz DC, Howden CW. Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther. 2021, 53:794-809. 10.1111\/apt.16295","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.08.001","article-title":"Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases","volume":"168","author":"Inatomi N","year":"2016","unstructured":"Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016, 168:12-22. 10.1016\/j.pharmthera.2016.08.001","journal-title":"Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases","volume":"24","author":"Oshima T","year":"2018","unstructured":"Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018, 24:334-44. 10.5056\/jnm18029","journal-title":"J Neurogastroenterol Motil"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1304552","article-title":"Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis","volume":"14","author":"Dong Y","year":"2023","unstructured":"Dong Y, Xu H, Zhang Z, Zhou Z, Zhang Q. Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis. Front Pharmacol. 2023, 14:1304552. 10.3389\/fphar.2023.1304552","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13331","article-title":"Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis","volume":"42","author":"Ashida K","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al.. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015, 42:685-95. 10.1111\/apt.13331","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida K","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, et al.. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016, 43:240-51. 10.1111\/apt.13461","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i14.1550","article-title":"Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole","volume":"24","author":"Ashida K","year":"2018","unstructured":"Ashida K, Iwakiri K, Hiramatsu N, et al.. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018, 24:1550-61. 10.3748\/wjg.v24.i14.1550","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17255","article-title":"Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis","volume":"57","author":"Cho YK","year":"2023","unstructured":"Cho YK, Kim JH, Kim HS, et al.. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023, 57:72-80. 10.1111\/apt.17255","journal-title":"Aliment Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5056\/jnm22104","article-title":"Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: a multicenter double-blind randomized controlled trial","volume":"29","author":"Kim JS","year":"2023","unstructured":"Kim JS, Seo SI, Kang SH, et al.. Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: a multicenter double-blind randomized controlled trial. J Neurogastroenterol Motil. 2023, 29:58-64. 10.5056\/jnm22104","journal-title":"J Neurogastroenterol Motil"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial","volume":"164","author":"Laine L","year":"2023","unstructured":"Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2023, 164:61-71. 10.1053\/j.gastro.2022.09.041","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15185","article-title":"Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis","volume":"49","author":"Lee KJ","year":"2019","unstructured":"Lee KJ, Son BK, Kim GH, et al.. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019, 49:864-72. 10.1111\/apt.15185","journal-title":"Aliment Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i44.6294","article-title":"Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis","volume":"28","author":"Lee KN","year":"2022","unstructured":"Lee KN, Lee OY, Chun HJ, et al.. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol. 2022, 28:6294-309. 10.3748\/wjg.v28.i44.6294","journal-title":"World J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15062","article-title":"Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis","volume":"49","author":"Oshima T","year":"2019","unstructured":"Oshima T, Arai E, Taki M, et al.. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019, 49:140-6. 10.1111\/apt.15062","journal-title":"Aliment Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5365-0","article-title":"Short-term symptomatic relief in gastroesophageal reflux disease: a comparative study of esomeprazole and vonoprazan","volume":"64","author":"Sakurai K","year":"2019","unstructured":"Sakurai K, Suda H, Fujie S, et al.. Short-term symptomatic relief in gastroesophageal reflux disease: a comparative study of esomeprazole and vonoprazan. Dig Dis Sci. 2019, 64:815-22. 10.1007\/s10620-018-5365-0","journal-title":"Dig Dis Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis","volume":"69","author":"Xiao Y","year":"2020","unstructured":"Xiao Y, Zhang S, Dai N, et al.. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020, 69:224-30. 10.1136\/gutjnl-2019-318365","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06141-5","article-title":"Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis","volume":"66","author":"Cheng Y","year":"2021","unstructured":"Cheng Y, Liu J, Tan X, et al.. Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis. Dig Dis Sci. 2021, 66:19-28. 10.1007\/s10620-020-06141-5","journal-title":"Dig Dis Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5056\/jnm18139","article-title":"Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker","volume":"25","author":"Mori H","year":"2019","unstructured":"Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 2019, 25:6-14. 10.5056\/jnm18139","journal-title":"J Neurogastroenterol Motil"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.13104","article-title":"Proton pump inhibitor versus potassium-competitive acid blocker in gastroesophageal reflux disease","volume":"8","author":"Oshima T","year":"2024","unstructured":"Oshima T. Proton pump inhibitor versus potassium-competitive acid blocker in gastroesophageal reflux disease. JGH Open. 2024, 8:e13104. 10.1002\/jgh3.13104","journal-title":"JGH Open"},{"key":"ref27","article-title":"Potassium-competitive acid blockers: present and potential utility in the armamentarium for acid peptic disorders","volume":"18","author":"Wong N","year":"2022","unstructured":"Wong N, Reddy A, Patel A. Potassium-competitive acid blockers: present and potential utility in the armamentarium for acid peptic disorders. Gastroenterol Hepatol (N Y). 2022, 18:693-700.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref28","article-title":"Potassium-competitive acid blockers and gastroesophageal reflux disease","volume":"19","author":"Armstrong D","year":"2023","unstructured":"Armstrong D. Potassium-competitive acid blockers and gastroesophageal reflux disease. Gastroenterol Hepatol (N Y). 2023, 19:295-8.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.870817","article-title":"Novel potassium-competitive acid blocker, tegoprazan, protects against colitis by improving gut barrier function","volume":"13","author":"Son M","year":"2022","unstructured":"Son M, Park IS, Kim S, et al.. Novel potassium-competitive acid blocker, tegoprazan, protects against colitis by improving gut barrier function. Front Immunol. 2022, 13:870817. 10.3389\/fimmu.2022.870817","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxad009","article-title":"Proton pump inhibitors: understanding the associated risks and benefits of long-term use","volume":"80","author":"Thurber KM","year":"2023","unstructured":"Thurber KM, Otto AO, Stricker SL. Proton pump inhibitors: understanding the associated risks and benefits of long-term use. Am J Health Syst Pharm. 2023, 80:487-94. 10.1093\/ajhp\/zxad009","journal-title":"Am J Health Syst Pharm"},{"key":"ref31","article-title":"Long-term consequences of chronic proton pump inhibitor use","volume":"38","author":"Galdo JA","year":"2013","unstructured":"Galdo JA. Long-term consequences of chronic proton pump inhibitor use. US Pharm. 2013, 38:38-42.","journal-title":"US Pharm"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi P","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J, et al.. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019, 157:682-91.e2. 10.1053\/j.gastro.2019.05.056","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S144149","article-title":"Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis","volume":"11","author":"Uemura N","year":"2018","unstructured":"Uemura N, Kinoshita Y, Haruma K, Yao T, Kushima R, Kanoo T. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Clin Exp Gastroenterol. 2018, 11:51-6. 10.2147\/CEG.S144149","journal-title":"Clin Exp Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/273371-comparison-of-potassium-competitive-acid-blockers-and-proton-pump-inhibitors-in-patients-with-gastroesophageal-reflux-disease-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:24:10Z","timestamp":1721694250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/273371-comparison-of-potassium-competitive-acid-blockers-and-proton-pump-inhibitors-in-patients-with-gastroesophageal-reflux-disease-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.65141","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}